Consistently, exogenous SPARC administration has demonstrated a suppression of growth in a spectrum of cancers including pancreatic cancer (32), colorectal cancer (33), neuroblastomas (34), and leukemia (35). This evidence concerns the gene SPARC and colorectal cancer.